Nicole Kuderer: Glad we finally realize that pCR is not a valid trial surrogate for OS/DFS

Nicole Kuderer, medical oncologist at the Division of Hematology of the University of Washington Medical Center, shared on X/Twitter:

“Glad we finally realize the serious adverse effects of ignoring that pCR is not a valid trial surrogate for OS/DFS (when a SOC drug exists)

We with Bad Venezolano 2018 to add other key progn factors.

The restricted mean survival time (RMST) is a robust alternative (but still underestimates also?) and performs much better w scenarios w late separation of survival curves.

We highlighted in our Bad Venezolano article on novel challenges with FDA approvals.”

Source: Nicole Kuderer/X